TLDR

PMGC Holdings (ELAB) jumped over 100% in pre-market trading after its subsidiary, NorthStrive Biosciences, amended a license deal with Korean biotech MOA Life Plus.
The amendment updates timing and development milestones for two clinical programs: EL-32 and EL-22.
NorthStrive could potentially skip a Phase 1 trial and move directly to Phase 2 for these programs.
To do so, NorthStrive must provide MOA Life Plus written scientific documentation supporting a Phase 2 trial.
The stock had closed down 11% at $1.67 before the after-hours surge, touching a three-year low of $1.62 earlier in the session.

PMGC Holdings (ELAB) surged more than 100% in after-hours and pre-market trading on Friday after its subsidiary NorthStrive Biosciences signed a third amendment to its license agreement with MOA Life Plus, a Korean biotechnology company.

PMGC Holdings Inc., ELAB

The stock gained 87% to $3.13 in after-hours trading, then extended those gains to around $3.35 in pre-market activity. That’s a sharp reversal from a rough regular session, where ELAB closed down 11% at $1.67 — after touching a three-year low of $1.62.

The license agreement covers two human health programs: EL-32 and EL-22. These are compounds that NorthStrive licenses from MOA Life Plus for clinical development.

The third amendment updates the timing and key development milestones tied to both programs. The company said the changes align the development schedule with its research, regulatory, and operational expectations.

The more eye-catching detail is what the amendment says about Phase 1 trials. Under the updated terms, NorthStrive could skip the Phase 1 stage entirely for one or both programs.

To do that, NorthStrive would need to provide MOA Life Plus with written documentation that provides scientific support for moving directly to a Phase 2 trial. If that documentation is accepted, NorthStrive would be excused from meeting its Phase 1 development milestone.

Skipping Phase 1 — which typically tests safety in healthy volunteers — is not standard, but it can happen in certain circumstances, such as when existing data from prior studies or related compounds already covers the safety profile.

What the Amendment Covers

NorthStrive is a wholly owned subsidiary of PMGC Holdings. The original license agreement gave NorthStrive development rights to EL-32 and EL-22 from MOA Life Plus, which is based in South Korea.

This is the third time the agreement has been amended, suggesting an ongoing and evolving working relationship between the two companies.

PMGC said the update “reinforces the company’s commitment to disciplined development planning.” The language signals that the revised milestones are intended to reflect a more realistic and structured path forward rather than an acceleration for its own sake.

Where the Stock Stands

The stock’s move is dramatic given where it was heading into the announcement. ELAB hit a three-year low during the regular session on Friday before closing at $1.67.

The after-hours and pre-market surge pulled the stock back above $3.00. Pre-market activity showed ELAB trading around $3.35, representing a gain of more than 100% from that $1.67 close.

Other pre-market movers on the day included Iterum Therapeutics (ITRM), up 159.8%, and Zeta Network Group (ZNB), up 47.2%, though those moves had different catalysts.

For ELAB specifically, the NorthStrive amendment appears to be the primary driver behind the jump. No other material news from PMGC Holdings was reported around the same time.

The post Why did PMGC Holdings (ELAB) Stock Rally Over 100%? appeared first on CoinCentral.

---

Filed under: News - @ March 30, 2026 10:27 am